| 颜丽华,骆小冬,陈烁淳,余馨盈,邱子仪,陈奕昕,陈采荷,宋步志,李颖嘉.经腹肠道超声监测维得利珠单抗治疗中-重度溃疡性结肠炎效果[J].中国医学影像技术,2025,41(10):1687~1690 |
| 经腹肠道超声监测维得利珠单抗治疗中-重度溃疡性结肠炎效果 |
| Transabdominal bowel ultrasound for monitoring efficacy of vedolizumab treatment in patients with moderate-to-severe ulcerative colitis |
| 投稿时间：2025-03-03 修订日期：2025-10-12 |
| DOI：10.13929/j.issn.1003-3289.2025.10.017 |
| 中文关键词: 结肠炎,溃疡性 抗体,单克隆,人源化 治疗转归 结肠,乙状 超声检查 |
| 英文关键词:colitis, ulcerative antibodies, monoclonal, humanized treatment outcome colon, sigmoid ultrasonography |
| 基金项目:广东省卫生健康适宜技术推广项目(202207011114072848)。 |
|
| 摘要点击次数: 116 |
| 全文下载次数: 37 |
| 中文摘要: |
| 目的 观察经腹肠道超声用于监测维得利珠单抗治疗中-重度溃疡性结肠炎效果的价值。方法 回顾性纳入Mayo内镜评分(MES)≥2并接受维得利珠单抗治疗的47例溃疡性结肠炎患者,分别于基线期、诱导治疗结束时、维持治疗3、6个月后接受经腹肠道超声检查,并于基线期及维持治疗6个月后接受结肠镜检查。根据维持治疗6个月后结肠镜结果将其分为改善组(MES≤1或MES降低≥1,n=25)与无改善组(n=22);比较组间及组内超声所见。结果 组间基线期乙状结肠超声表现差异均无统计学意义(P均＞0.05);诱导治疗结束时组间肠壁厚度,维持治疗3个月后组间Limberg分级及肠周异常淋巴结,以及维持治疗6个月后组间肠壁层次结构均存在差异(P均＜0.05)。改善组内,相比基线期,治疗后各时间点肠壁厚度均有所改善,维持治疗3、6个月后Limberg分级改善,维持治疗6个月后肠壁层次结构、肠周异常淋巴结及脂肪组织水肿均改善(P均＜0.05);而无改善组观察期内超声所见未见显著改变(P均＞0.05)。结论 肠道超声可用于准确监测维得利珠单抗治疗中-重度溃疡性结肠炎效果。 |
| 英文摘要: |
| Objective To observe the value of transabdominal bowel ultrasound for monitoring therapeutic efficacy of vedolizumab in patients with moderate-to-severe ulcerative colitis. Methods Totally 47 ulcerative colitis patients with Mayo endoscopic score (MES)≥2 and treated with vedolizumab were retrospectively included. Transabdominal bowel ultrasound examinations were performed at baseline, at the end of induction therapy, also 3 and 6 months after maintenance therapy, while colonoscopy was performed at baseline and 6 months after maintenance therapy. According to colonoscopy results 6 months after maintenance therapy, the patients were divided into improved group (MES≤1 or MES reduction≥1, n=25) and non-improved group (n=22), and ultrasonic findings of sigmoid colon were compared between and within groups. Results At baseline, no significant difference of ultrasonic findings of sigmoid colon was observed between groups (all P＞0.05), whereas differences of bowel wall thickness at the end of induction therapy, of Limberg grade and abnormal perienteric lymph nodes 3 months after maintenance therapy, as well as bowel wall stratification 6 months after maintenance therapy were noticed between groups (all P＜0.05). Within improved group, compared with those in baseline, bowel wall thickness improved at all time points after the beginning of treatment, Limberg grade improved 3 and 6 months after maintenance therapy, while bowel wall stratification, abnormal perienteric lymph node and perienteric fat edema improved 6 months after maintenance therapy (all P＜0.05). Meanwhile, no significant change of ultrasonic findings of sigmoid colon was observed in non-improved group during the above periods (all P＞0.05). Conclusion Transabdominal bowel ultrasound could be used to accurately monitor the therapeutic efficacy of vedolizumab in patients with moderate-to-severe ulcerative colitis. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
